


# CAR T-CELL CLINICAL TRIALS SUPPORT AT UHN

## WHAT IS CAR T-CELL THERAPY?




T-cells are immune effector cells (IEC) that can be genetically manipulated to target antigens on cells, leading to activation and cytotoxicity to the target cells.

These **chimeric antigen receptor (CAR) T-cells** have revolutionized the care of patients with lymphoma, leukemia and other cancers, but are also showing promise in non-malignant diseases, such as SLE.

## THE CAR T PROCESS

This is a complex, resource-intensive, expensive treatment requiring expert handling of both cells and patients. Management of toxicities such as cytokine release syndrome (CRS) and unique neurotoxicities require specialized training and monitoring.



Guerra. Int.J.Mol.Sci. 2022

**CAR T-cell processes must adhere to quality standards under the Foundation of Accreditation for Cellular Therapy (FACT) with mandated 15 year follow-up**



## CURRENT CAR T-CELL ACTIVITY AT UHN

CAR T volumes at Princess Margaret (PM)

- 74** Patients completed treatments in 2023 (lymphoma, leukemia)
- 18** Total cell therapy trials currently open



*Several new cancer indications anticipated to become standard of care in 2025*

### CAR T resources

- 6** Beds for Inpatient Cell Therapy care
- 6** Chairs in Day Hospital Outpatient care
- 1** Cell Processing Laboratory (Orsino) at PM
- 1** Apheresis unit (shared with dialysis) at TGH
- 3** Cell therapy quality managers for cell therapy accreditation oversight

*All lab and clinical providers require specialized training and annual competency assessments*

## HOW TO GET SUPPORT FOR YOUR CAR T OR OTHER CELL THERAPY TRIALS (non-cancer):

- Please note that there are many regulations and standards required for safe IEC product and patient management
- The PM IEC Advisory Group and Cancer Clinical Research Unit (CCRU), comprised of clinicians, quality specialists, and trials experts familiar with IEC therapy, can provide guidance and clinical support, within capacity limitations
- Submit form in link below as early as possible in your trial process so we can determine feasibility and needs

**CONTACT FOR FORM:**  
[ccru-celltherapystudies@uhn.ca](mailto:ccru-celltherapystudies@uhn.ca)



### FOR GENERAL IEC INFO:

- [Anuj.Singla@uhn.ca](mailto:Anuj.Singla@uhn.ca) (Manager, Cancer Clinical Research Unit (CCRU) Cell Therapy)
- [Christine.Chen@uhn.ca](mailto:Christine.Chen@uhn.ca) (Medical Director, Clinical Cell Therapy Program at PM)
- [Pmcellulartherapy@uhn.ca](mailto:Pmcellulartherapy@uhn.ca) (IEC clinical coordinator)